Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 vs Rituximab in Rheumatoid Arthritis
NCT01682512Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2012
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of MabionCD20 in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Started Sep 2012; status: terminated.
02
Drugs
MabionCD20
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01682512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682512.